An induction versus no-induction protocol in anticalcineurin-based immunosuppression using very low-dose steroids.
Charpentier
B
B
University Hospital of Bicêtre, Le Kremlin-Bicêtre, France.
D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D001379:Azathioprine / Q000627:therapeutic use; D019703:Calcineurin / Q000276:immunology*; D004359:Drug Therapy, Combination; D005260:Female; D006085:Graft Survival / Q000187:drug effects / Q000276:immunology*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality / Q000502:physiology; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D011183:Postoperative Complications / Q000453:epidemiology; D012086:Reoperation; D013256:Steroids / Q000627:therapeutic use*; D015996:Survival Rate; D016559:Tacrolimus / Q000627:therapeutic use; D013997:Time Factors
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D013256:Steroids; D019703:Calcineurin; D001379:Azathioprine; D016559:Tacrolimus